Vertex Pharmaceuticals (VRTX) Current Assets (2009 - 2026)

Vertex Pharmaceuticals has reported Current Assets for 18 years, with the latest figure at $12.5 billion in Q2 2026.

• On a quarterly basis, Current Assets rose 20.29% year-over-year to $12.5 billion in Q2 2026; TTM through Jun 2026 was $12.5 billion, a 20.29% increase from a year earlier, with the FY2025 full-year figure at $11.2 billion, up 16.72% from the prior year.
• Current Assets was $12.5 billion for Q2 2026 at Vertex Pharmaceuticals, up from $11.7 billion in the prior quarter.
• The five-year high for Current Assets was $14.7 billion in Q3 2023, with the low at $8.9 billion in Q2 2024.
• Average Current Assets over 5 years is $11.7 billion, with a median of $11.6 billion recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Current Assets jumped 38.62% in 2022, then tumbled 35.55% in 2024.
• Over 5 years, Current Assets stood at $13.2 billion in 2022, then increased by 6.87% to $14.1 billion in 2023, then slumped by 32.15% to $9.6 billion in 2024, then advanced by 16.72% to $11.2 billion in 2025, then climbed by 11.99% to $12.5 billion in 2026.
• The last three Current Assets figures came in at $12.5 billion (Q2 2026), $11.7 billion (Q1 2026), and $11.2 billion (Q4 2025), per Business Quant data.